Patents Assigned to Pfizer
  • Glucagon receptor modulators
    Patent number: 8507533
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: August 13, 2013
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Esther Cheng Yin Lee, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
  • N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    Patent number: 8507681
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: August 13, 2013
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • Treatment of Pulmonary Hypertension
    Publication number: 20130203767
    Abstract: This invention relates to the use of certain cyclic guanosine 3?,5?-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 8, 2013
    Applicant: Pfizer Inc.
    Inventor: Pfizer Inc.
  • HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
    Publication number: 20130196952
    Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 1, 2013
    Applicant: PFIZER INC.
    Inventors: Mark Edward Bunnage, Andrew Simon Cook, Jingrong Jean Cui, Kevin Nell Dack, Judith Gail Deal, Danlin Gu, Mingying He, Patrick Stephen Johnson, Ted William Johnson, Phuong Thi Quy Le, Cynthia Louise Palmer, Hong Shen
  • 3-AMINOCYCLOPENTANECARBOXAMIDES AS CHEMOKINE RECEPTOR AGONISTS
    Publication number: 20130197008
    Abstract: There is provided a compound of Formula I(a) or I(b): or a pharmaceutically acceptable salt thereof, wherein the various substitutents are defined herein.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 1, 2013
    Applicant: Pfizer Inc.
    Inventors: Robert O. HUGHES, Rajesh V. Devraj, Donald J. Rogier, John I. Trujillo, Steve R. Turner, Wei Huang
  • N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
    Publication number: 20130190334
    Abstract: The invention provides a compound of Formula (I) Z N N O N O A1R2 R1 R3R 3 L A2 (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3,Z, A1, L and A 5 2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: September 20, 2011
    Publication date: July 25, 2013
    Applicant: PFIZER INC.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • Methods of treating cancer with human monoclonal antibodies to CTLA-4
    Patent number: 8491895
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: July 23, 2013
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Pyrimidones for Treatment of Potassium Channel Related Diseases
    Publication number: 20130184294
    Abstract: The present invention relates to compounds of Formula I as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.
    Type: Application
    Filed: September 7, 2011
    Publication date: July 18, 2013
    Applicant: Pfizer Inc.
    Inventors: Isao Sakurada, Lei Zhang
  • Carboxamide derivatives as muscarinic receptor antagonists
    Patent number: 8486992
    Abstract: The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: July 16, 2013
    Assignee: Pfizer Limited
    Inventors: Paul Alan Glossop, Simon John Mantell, Anthony Wood, Christine Anne Louise Watson
  • KAT II inhibitors
    Patent number: 8487104
    Abstract: The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3, 4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: July 16, 2013
    Assignee: Pfizer Inc.
    Inventors: Amy B Dounay, Christopher J Helal, Jamison B Tuttle, Patrick R Verhoest
  • Treatment of chronic prostatitis
    Patent number: 8481036
    Abstract: The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with chronic prostatitis and/or chronic pelvic pain syndrome.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: July 9, 2013
    Assignee: Pfizer Inc.
    Inventor: David Louis Shelton
  • IgE CH3 peptide vaccine
    Patent number: 8475801
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: July 2, 2013
    Assignee: Pfizer Vaccines, LCC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
  • Substituted Heteroaryls
    Publication number: 20130165452
    Abstract: The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.
    Type: Application
    Filed: February 22, 2013
    Publication date: June 27, 2013
    Applicant: PFIZER INC.
    Inventor: Pfizer Inc.
  • Novel Sultam Compounds
    Publication number: 20130150376
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: March 31, 2011
    Publication date: June 13, 2013
    Applicant: PFIZER INC.
    Inventors: Michael Aaron Brodney, Ivan Viktorovich Efremov, Christopher John Helal, Brian Thomas O'Neill
  • Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers
    Publication number: 20130150391
    Abstract: The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.
    Type: Application
    Filed: June 20, 2011
    Publication date: June 13, 2013
    Applicant: PFIZER INC.
    Inventors: Michelle Marie Claffey, Jennifer Elizabeth Davoren, John Adams Lowe, III, Robert Joseph Mather
  • Polynucleotides encoding engineered ketoreductase polypeptides
    Patent number: 8455230
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of stereospecifically reducing (R)-2-methylpentanal to (R)-2-methylpentanol. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to produce (R)-2-methylpentanol and related compounds.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: June 4, 2013
    Assignees: Codexis, Inc., Pfizer, Inc.
    Inventors: Rama Voladri, Owen Gooding, Stephan Jenne, Emily Mundorff
  • Benzofuranyl derivatives
    Patent number: 8455496
    Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: June 4, 2013
    Assignee: Pfizer Inc.
    Inventors: Jeffrey Allen Pfefferkorn, Anthony Lai Ling
  • CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
    Publication number: 20130129753
    Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 23, 2013
    Applicant: PFIZER INC.
    Inventor: PFIZER INC.
  • Tricyclic compounds, compositions, and methods
    Patent number: 8445520
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: May 21, 2013
    Assignee: Pfizer Inc.
    Inventors: Hengmiao Cheng, Xiao Hu, Kevin D. Jerome, Mark G. Obukowicz, Lisa Maria Olson, Paul V. Rucker, Ronald Keith Webber
  • Treatment of Male Sexual Dysfunction
    Publication number: 20130121923
    Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Application
    Filed: January 16, 2013
    Publication date: May 16, 2013
    Applicant: PFIZER INC.
    Inventor: PFIZER INC.